Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mónica Corral
Observed names:
M Corral,
M. Corral,
Monica Corral
Institution:
Hospital Clínico Universitario Lozano Blesa
Observed institutions:
Hospital Universitario Miguel Servet,
Hospital Clínico Universitario Lozano Blesa,
Grupo Español Multidisciplinar de Melanoma
ORCID:
0000-0002-6443-8701
Observed ORCID:
0000-0002-6443-8701
OpenAlex ID:
A5105927482
Brain Metastases from Colorectal Carcinoma
2001
·
Miriam Zorrilla
, Vicente Alonso
, et al.
·
Tumori Journal
·
20
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
2021
·
Mª del Carmen Álamo
, Sebastian Ochenduszko
, et al.
·
OncoTargets and Therapy
·
6
PDF
A Phase II Study of Sequential Docetaxel Followed by Doxorubicin/Cyclophosphamide as First-Line Chemotherapy For Metastatic Breast Cancer
2003
·
Antonio Antón
, Javier Hornedo
, et al.
·
Clinical Breast Cancer
·
6
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma
2023
·
Lucía Trilla-Fuertes
, Angelo Gámez-Pozo
, et al.
·
Cancers
·
5
PDF
Oral vinorelbine (NVBO) in combination with trastuzumab (HER) in metastatic breast cancer (MBC): Data on efficacy and safety when administered in first- or second-line treatment.
2010
·
J. J. Illarramendi
, I. Blancas
, et al.
·
Journal of Clinical Oncology
·
5
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma
2023
·
Lucía Trilla-Fuertes
, Angelo Gámez-Pozo
, et al.
·
International Journal of Molecular Sciences
·
3
PDF
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer
2003
·
Angel Artal-Cortés
, Javier Martínez-Trufero
, et al.
·
Anti-Cancer Drugs
·
2
P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)
2016
·
C. Pericay
, N. Martínez-Lago
, et al.
·
Annals of Oncology
·
1
Immune classification of advanced melanoma identifies non-responders to anti-PD1 therapy
2026
·
Angelo Gámez-Pozo
, Lucía Trilla-Fuertes
, et al.
·
Cancer Immunology Immunotherapy
PDF
Abstract 5416: RNA-seq and proteomics to identify response to immunotherapy in advanced melanoma: a Spanish Melanoma Group Study
2022
·
Lucia Trilla-Fuertes
, Guillermo Prado-Vazquez
, et al.
·
Cancer Research
Efficacy of immunotherapy in patients with metastatic uveal melanoma
2021
·
Juan Verdún
, Teresa Puértolas
, et al.
·
DIGITAL.CSIC (Spanish National Research Council (CSIC))
Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice.
2020
·
Maria Carmen Álamo de la Gala
, Sebastian Ochenduszko
, et al.
·
Journal of Clinical Oncology
Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA).
2016
·
Carles Pericay
, Nieves Purificacion Martinez
, et al.
·
Journal of Clinical Oncology
9113 POSTER Total Direct and Segmented Medical Cost-of-Care for Stage IV (Adv) Non-Small Cell Lung Cancer (NSCLC) in a Private Insurance Population
2011
·
J. Koeller
, A. Bell
, et al.
·
European Journal of Cancer
El que siembra sangre
2011
·
Arne Dahl
, Mónica Corral
, et al.
·
Ediciones Destino eBooks
P-25 Feasibility trial of protracted (120') gemcitabine infusion in non-small cell lung cancer (NSCLC)
2003
·
Rosana Grandez
, Javier Martínez
, et al.
·
Lung Cancer
[Current clinical use of hematopoietic growth factors].
1995
·
F J Ramos
, M C del Cañizo
, et al.
·
PubMed
Show more works
View as search
Works count:
17
Citation count:
48
H-index:
5
I10-index:
1
Year
Topic
Type